Symbiomix pops out of stealth mode with $41M and a looming PhIII

John Carroll

In the little more than two years since its launch, Therapeutics has successfully navigated a midstage study for a sole-asset antibiotic, positioning it for a Phase III start in Q2. And now it's ready to jump out of as it prepares for a make-or-break move for an anti-infective that has been in use for years–just not in the U.S.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS